I reported previously (see here) on the innovative NexoBrid treatment for severe burns from Israel’s MediWound. MediWound has just announced positive top line results of its pivotal U.S. Phase 3 clinical study. Dead skin was completely removed from 93% of … Continue reading →

The US Biomedical Advanced Research and Development Authority (BARDA) has invested $43 million in Israel’s MediWound to develop its NexoBrid product for the treatment of mustard gas injuries. In 2015 BARDA invested $112 million to help MediWound develop NexoBrid for … Continue reading →

The Biomedical Advanced Research & Development Authority (BARDA) – part of the US Department of Health – has awarded a $112 million contract to Israel’s Mediwound. BARDA will use Mediwound’s NexoBrid product in major incidents, to remove dead tissues from … Continue reading →

Israel’s MediWound has commenced a Phase 3 study to valuate the efficacy and safety of its innovative NexoBrid treatment for severe burns in children.  The study plans to be conducted in around 25 sites in Europe and Israel.  NexoBrid removes … Continue reading →

The European Medicines Agency (EMA) has recommended approval of third degree burns treatment NexoBrid, developed by Israel’s MediWound Ltd. NexoBrid is a gel made of enzymes that removes burnt tissue, reduces the risk of infection and shortens recovery time. http://www.globes.co.il/serveen/globes/docview.asp?did=1000786167&fid=1725